Skip to main content
. 2020 May 14;6(7):e201250. doi: 10.1001/jamaoncol.2020.1250

Figure 2. Progression-Free Survival (PFS) and Overall Survival .

Figure 2.

For all patients, median PFS, 9.3 months (95% CI, 7.2-11.4 months) (A); median OS, 26.2 months (95% CI, 21.9-30.4 months) (B). Tick marks indicate censoring. PFS (C) and OS (D) according to the cohorts, defined by age, performance status, and age-adjusted Charlson Comorbidity Index as follows: cohort 1, aged ≥81 years; cohort 2, aged 75-80 years and age-adjusted Charlson Comorbidity Index (a-CCI) ≥ 6 points or PS ≥ 1; and cohort 3, aged 20-74 years and a-CCI ≥ 6 points or PS ≥ 2. Median PFS and OS were as follows: cohort 1, 8.6 months (95% CI, 5.8-14.0 months) and 22.7 months (95% CI, 11.7-26.8 months); cohort 2, 11.3 months (95% CI, 7.5-12.2 months) and 34.6 months (95% CI, 23.6-37.5 months); cohort 3, 9.20 months (95% CI, 3.4-12.4 months) and 18.0 months (95% CI, 6.7-34.9 months).